Dicerna Pharmaceuticals PEG Ratio

Dicerna Pharmaceuticals (DRNA) currently reports a PEG ratio of 115.77. That is above the Healthcare sector average of 2.56. Use the charts on this page to explore Dicerna Pharmaceuticals's PEG ratio history and peer comparisons.

Dicerna Pharmaceuticals's PEG ratio of 115.77 is higher than the Healthcare sector average of 2.56. That is roughly 4422.7% above the sector mean. A reading higher peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

The PEG ratio is a valuation multiple that relates Dicerna Pharmaceuticals's market price to a fundamental measure such as earnings, sales, or book value. At 115.77, DRNA can look expensive or cheap only in context — versus its own history, growth rate, and Healthcare peers. Higher multiples often price in stronger expected growth; lower ones can signal value or concern.

Start with the current PEG ratio of 115.77, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 2.56. From there, open related valuation or income-statement pages for Dicerna Pharmaceuticals, and consider following DRNA for alerts when major investors trade the stock.

Dicerna Pharmaceuticals is classified in the Healthcare sector. On PEG ratio, it currently shows 115.77 versus a sector average near 2.56. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing DRNA with unrelated industries.